2018
Severe outcomes associated with respiratory viruses in newborns and infants: a prospective viral surveillance study in Jordan
Khuri-Bulos N, Lawrence L, Piya B, Wang L, Fonnesbeck C, Faouri S, Shehabi A, Vermund SH, Williams JV, Halasa NB. Severe outcomes associated with respiratory viruses in newborns and infants: a prospective viral surveillance study in Jordan. BMJ Open 2018, 8: e021898. PMID: 29780032, PMCID: PMC5961648, DOI: 10.1136/bmjopen-2018-021898.Peer-Reviewed Original ResearchMeSH KeywordsAdenoviridaeAntiviral AgentsFemaleHumansInfantIntensive Care UnitsJordanLength of StayMaleOxygen Inhalation TherapyPalivizumabParainfluenza Virus 1, HumanProspective StudiesRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesRespiratory Syncytial Virus, HumanRespiratory Tract InfectionsRhinovirusRisk FactorsConceptsLonger LOSLength of stayAcute respiratory infectionsIntensive care unitRespiratory syncytial virusOxygen therapyMechanical ventilationHospitalisation ratesICU admissionIllness severityRespiratory virusesMedical conditionsExtended breast feedingRSV vaccine developmentProspective cohort studyUnderlying medical conditionsChemotherapy-associated neutropeniaHuman parainfluenza virusesYears of ageCohort studyRespiratory symptomsBreast feedingRespiratory infectionsCare unitSyncytial virus
2016
Risk Factors for Loss to Follow-Up among People Who Inject Drugs in a Risk Reduction Program at Karachi, Pakistan. A Case-Cohort Study
Samo RN, Agha A, Shah SA, Altaf A, Memon A, Blevins M, Qian HZ, Vermund SH. Risk Factors for Loss to Follow-Up among People Who Inject Drugs in a Risk Reduction Program at Karachi, Pakistan. A Case-Cohort Study. PLOS ONE 2016, 11: e0147912. PMID: 26840414, PMCID: PMC4739707, DOI: 10.1371/journal.pone.0147912.Peer-Reviewed Original ResearchConceptsCase-cohort studyMale PWIDHarm reduction programsRisk reduction programsRisk factorsReduction programsNeedle/syringe exchangeProspective cohort studyMultivariable logistic regressionResource-limited settingsHistory of incarcerationCohort studyMedian ageIncidence rateSyringe exchangePWIDMale peopleYounger ageLogistic regressionYoung menMonthsKarachiMenActive outreachProgrammatic challenges
2005
Mode of Delivery and Other Maternal Factors Influence the Acquisition of Streptococcus mutans in Infants
Li Y, Caufield PW, Dasanayake AP, Wiener HW, Vermund SH. Mode of Delivery and Other Maternal Factors Influence the Acquisition of Streptococcus mutans in Infants. Journal Of Dental Research 2005, 84: 806-811. PMID: 16109988, DOI: 10.1177/154405910508400905.Peer-Reviewed Original ResearchConceptsMode of deliveryMaternal factorsS. mutansC-section infantsMaternal gestational ageProspective cohort studyS. mutans levelsMother-infant pairsCaesarean sectionCohort studyPerinatal eventsGestational ageMutans levelsCariogenic microbiotaDental cariesPerinatal influencesInfection experienceInfantsCariesFamily incomeStreptococcus mutansMutansPotential effectsDeliveryInitial acquisition
2004
Universal nevirapine upon presentation in labor to prevent mother-to-child HIV transmission in high prevalence settings
Stringer J, Sinkala M, Goldenberg RL, Kumwenda R, Acosta EP, Aldrovandi GM, Stout JP, Vermund SH. Universal nevirapine upon presentation in labor to prevent mother-to-child HIV transmission in high prevalence settings. AIDS 2004, 18: 939-943. PMID: 15060442, PMCID: PMC2745979, DOI: 10.1097/00002030-200404090-00012.Peer-Reviewed Original ResearchConceptsChild HIV transmissionUnknown HIV serostatusHIV serostatusHIV transmissionPreliminary efficacyLabour wardHIV DNA polymerase chain reactionSingle-dose nevirapinePrevention of motherProspective cohort studyEvidence of infectionHigh-prevalence settingsWeeks of lifeNevirapine administrationNevirapine coverageChild transmissionCohort studyComparison cohortAdherence ratesPrevalence settingsPolymerase chain reactionCord bloodDNA polymerase chain reactionHIVInfant specimens
2003
Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine
Stringer J, Sinkala M, Chapman V, Acosta EP, Aldrovandi GM, Mudenda V, Stout JP, Goldenberg RL, Kumwenda R, Vermund SH. Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine. AIDS 2003, 17: 1659-1665. PMID: 12853748, PMCID: PMC2745973, DOI: 10.1097/00002030-200307250-00010.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultBreast FeedingDrug Administration ScheduleFemaleHIV InfectionsHIV SeropositivityHumansInfant, NewbornInfectious Disease Transmission, VerticalLabor, ObstetricNevirapineObstetric Labor ComplicationsPregnancyPregnancy Complications, InfectiousProspective StudiesReverse Transcriptase InhibitorsRisk FactorsTime FactorsConceptsPerinatal HIV transmissionHIV transmissionInfant HIV infection statusNeonatal single-dose nevirapineMaternal drug doseSingle-dose nevirapineHIV infection statusProspective cohort studyPerinatal transmission rateOnset of laborMain outcome measuresMean drug concentrationWeeks of lifeRisk of transmissionNVP levelsNVP prophylaxisNVP syrupObstetrical clinicPerinatal transmissionCohort studyOral doseViral loadPregnant womenPolymerase chain reactionRisk factors